ResearcherAsan Medical CenterActive in the last 2 years
Se Jin Choi
Matched on ORCID iD 0000-0001-7327-6102; OpenAlex author ID A5040723886, A5126337330. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 6
- Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI characteristics and diagnostic implicat… Co-author DOI 10.1016/j.ejrad.2026.112735↗
- Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
- ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
- Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct CT and MRI Characteristics. Co-author DOI 10.3348/kjr.2023.0521↗
- Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… First author DOI 10.1002/jhbp.1192↗
- Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than conventional pancreatic ductal adenocarcinoma: … First author DOI 10.1016/j.humpath.2022.05.018↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jae Ho Byun · 6 shared papers, 2022–2026 · strength 1.24
- Paper Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI… DOI 10.1016/j.ejrad.2026.112735↗
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Jin Hee Kim · 5 shared papers, 2022–2026 · strength 1.06
- Paper Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI… DOI 10.1016/j.ejrad.2026.112735↗
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Seung Soo Lee · 5 shared papers, 2022–2026 · strength 1.06
- Paper Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI… DOI 10.1016/j.ejrad.2026.112735↗
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Seung‐Mo Hong · 5 shared papers, 2022–2025 · strength 0.96
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Paper Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct … DOI 10.3348/kjr.2023.0521↗
- Dae Wook Hwang · 4 shared papers, 2022–2026 · strength 0.88
- Paper Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI… DOI 10.1016/j.ejrad.2026.112735↗
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Hyoung Jung Kim · 4 shared papers, 2022–2025 · strength 0.79
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Paper Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct … DOI 10.3348/kjr.2023.0521↗
- Kyu‐pyo Kim · 3 shared papers, 2022–2025 · strength 0.60
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Paper Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic p… DOI 10.1002/jhbp.1192↗
- Jong Keon Jang · 3 shared papers, 2022–2025 · strength 0.60
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Paper Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic p… DOI 10.1002/jhbp.1192↗
- Changhoon Yoo · 3 shared papers, 2022–2025 · strength 0.60
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Paper Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic p… DOI 10.1002/jhbp.1192↗
- Song Cheol Kim · 3 shared papers, 2022–2025 · strength 0.60
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Panc… DOI 10.1245/s10434-024-16618-6↗
- Paper Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic p… DOI 10.1002/jhbp.1192↗
- Dong‐Wan Seo · 2 shared papers, 2022–2025 · strength 0.37
- Paper Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pa… DOI 10.1245/s10434-024-16437-9↗
- Paper Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic p… DOI 10.1002/jhbp.1192↗
- Dong Wook Kim · 2 shared papers, 2022–2023 · strength 0.36
- Paper Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct … DOI 10.3348/kjr.2023.0521↗
- Paper Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than convent… DOI 10.1016/j.humpath.2022.05.018↗
- Sung Joo Kim · 2 shared papers, 2022–2023 · strength 0.36
- Paper Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct … DOI 10.3348/kjr.2023.0521↗
- Paper Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than convent… DOI 10.1016/j.humpath.2022.05.018↗
- Ki Byung Song · 1 shared paper, 2026 · strength 0.28
- Dong Wan Seo · 1 shared paper, 2025 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.